BD a leading global medical technology company, announced today it has acquired MedKeeper, a provider of modern, cloud-based pharmacy management applications.
MedKeeper strategically complements BD's existing presence in the pharmacy – where the company has pioneered solutions in compounding, logistics workflow, controlled substance management and inventory optimization.
MedKeeper's platform will become part of the company's existing portfolio of connected medication management capabilities. By combining MedKeeper's platform with BD's broad technology expertise, the companies will work to optimize the preparation of compounded medications – a critical need in the pharmacy today.
"Preparing the right dose for patients requires a combination of factors – including personnel, training, and compliance. Pharmacy leaders require IV workflow management technology that is personalized to their needs and works within their environment. Adding MedKeeper to our portfolio will enable us to offer our customers easy to use, customizable solutions that make meaningful and incremental progress in IV workflow management."
Mike Garrison, Worldwide President of Medication Management Solutions at BD
Today, many pharmacies leverage a combination of both manual and technical tools for their IV workflow management system. Adding MedKeeper to BD's Medication Management Solutions portfolio will further strengthen the company's ability to deliver solutions that best meet customers' needs – now and in the future.
"Demands in today's pharmacy environment, such as COVID-impacted labor shortages and changing regulatory requirements, have further exacerbated the need for customizable pharmacy software solutions to support flexible, directed workflow, inventory tracking and reporting needs in sterile and non-sterile compounding," said Garrison. "Manual, time-consuming procedures that might once have been 'good enough' now can be replaced and augmented by software that enables pharmacists to provide a higher standard of care."
BD and MedKeeper will work to provide customers with flexibility and capabilities in meeting industry standards for preparing compounded medications, incorporating the latest regulatory guidance. Together, the companies are dedicated to ensuring that every customer has a workflow solution that best supports their environment and delivers efficiencies to their frontline clinicians.
The transaction is expected to be immaterial to BD's fiscal 2022 financial results.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.